American Journal of Alzheimer's Disease and Other Dementias®

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Register here to gain access to SAGE's 500+ Journals Online

Click here to sign up for SAGE Journal Email Alerts today!

Sign In to gain access to subscriptions and/or personal tools.
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Moretti, R.
Right arrow Articles by Cazzato, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Moretti, R.
Right arrow Articles by Cazzato, G.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
American Journal of Alzheimer's Disease and Other Dementias®, Vol. 19, No. 6, 333-339 (2004)
DOI: 10.1177/153331750401900607

Cholinesterase inhibition as a possible therapy for delirium in vascular dementia: A controlled, open 24-month study of 246 patients

Rita Moretti, MD

Paola Torre, MD

Rodolfo M. Antonello, MD

Tatiana Cattaruzza, MD

Giuseppe Cazzato, MD

Dipartimento di Medicina Clinica e Neurologia, Ambulatorio Disturbi Cognitivi, Università degli Studi di Trieste, Trieste, Italy

The goal of this study was to determine whether rivastigmine, a dual inhibitor of acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE), has any effect on delirium in vascular dementia (VaD). The results from this follow-up study suggest that although delirium is frequent in elderly, cognitively impaired patients, it might not be a simple consequence of acute disease and hospitalization. Rather, delirium can be secondary to brain damage and to metabolic disturbances. According to the Lewy body dementia model, delirium could be induced by a lack of acetylcholine in the brain. Rivastigmine may help reduce the frequency of delirium episodes and help shorten their duration. Additional studies are required to better define the causes of delirium, which currently has no definitive treatment.

Key Words: delirium • cholinesterase inhibition • rivastigmine • vascular dementia


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 J. Neurol. Neurosurg. PsychiatryHome page
C Thomas, U Hestermann, S Walther, U Pfueller, M Hack, P Oster, C Mundt, and M Weisbrod
Prolonged activation EEG differentiates dementia with and without delirium in frail elderly patients
J. Neurol. Neurosurg. Psychiatry, February 1, 2008; 79(2): 119 - 125.
[Abstract] [Full Text] [PDF]

Home page
 J. Neuropsychiatry Clin. Neurosi.Home page
D. Meagher and P. T. Trzepacz
Phenomenological Distinctions Needed in DSM-V: Delirium, Subsyndromal Delirium, and Dementias
J Neuropsychiatry Clin Neurosci, November 1, 2007; 19(4): 468 - 470.
[Full Text] [PDF]